Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.msard.2021.102983 http://scihub22266oqcxt.onion/10.1016/j.msard.2021.102983 33990054!8093161!33990054     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33990054&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mult+Scler+Relat+Disord 2021 ; 52 (ä): 102983 Nephropedia Template TP {{tp|p=33990054|t=2021. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab |pdf=|usr=}}{{33990054}} gab.com Text COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab JO: Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=33990054 #FOAvip Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination. Twit Text FOAVip COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab ????Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=33990054 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33990054 #FOAvip English Wikipedia <ref>{{Cite pmid|33990054}}</ref> COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab #MMPMID33990054 Buttari F; Bruno A; Dolcetti E; Azzolini F; Bellantonio P; Centonze D; Fantozzi R Mult Scler Relat Disord 2021[Jul]; 52 (ä): 102983 PMID33990054show ga Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination. |*COVID-19[MESH] |*Multiple Sclerosis[MESH] |Antibodies, Monoclonal, Humanized[MESH] |COVID-19 Vaccines[MESH] |Cladribine[MESH] |Humans[MESH]COVID-19 vaccines in multiple sclerosis treated with cladribine or ocr(epmc).pdf DeepDyve Pubget Overpricing